Abstract
Result: The PK and PD were similar between treatments, with the 90% CI for the ratios of geometric least squares means completely contained in the prespecified bioequivalence limit of 0.80-1.25 (Table). Adverse events were similar for LY IGlar and IGlar. No safety concernswere noted in clinical laboratory, vital signs, or ECG data. Conclusion: These studies demonstrate similarity in the PK and PD properties of LY IGlar and IGlar.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
